Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
Launched by MEDICAL UNIVERSITY OF VIENNA · Sep 8, 2008
Trial Information
Current as of June 25, 2025
Suspended
Keywords
ClinConnect Summary
Women in group A will undergo controlled ovarian stimulation according to the following protocol:
Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. dai...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 40
- • Informed consent
- • Indication for IVF-ET
- Exclusion Criteria:
- • Inability to understand written informed consent form
- • Personal history of ovarian hyperstimulation syndrome
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Johannes C. Huber, MD, PhD
Study Director
Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials